NPM1 and acute myeloid leukemia: NPM1, one of the most commonly mutated genes in de novo AML, is mutated in 35% of patients and is associated with a favorable prognosis in newly diagnosed AML, but with a poor prognosis in relapsed or refractory (R/R) AML [28–31].